Study of N-homocysteinylation of Key Proteins in Alzheimer's Disease
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- MAP1 homocysteinylation level
研究概览
简要总结
Alzheimer's disease (AD) is the leading cause of dementia in France. It is a multifactorial pathology, combining genetic and environmental risk factors. Homocysteine, a sulfur-containing amino acid belonging to the methionine-monocarbon cycle, has frequently been found at high levels in neurodegenerative diseases, and in AD in particular. It has been shown on human brain sections that the interaction of homocysteine with tau and MAP1, two key AD proteins, was significantly higher in AD patients than in controls, and corresponded to an N-homocysteinylation type interaction.
This is a prospective study, the main objective of which is to compare MAP1 N-homocysteinylation levels in fibroblasts from individuals with AD versus disease-free cell lines.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Other
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age > 18 years
- •Age of onset of AD < 75 years
- •Person with AD with positive CSF biomarkers
- •Person who has previously benefited from an analysis of AD genetic characteristics (APP, PSEN1, PSEN2, TREM2, ABCA7, SORL1 genes and ApoE status) and an analysis of monocarbon metabolism genes in the case of biochemical abnormalities by clinical exome, targeted panel or complete exome, and for whom the data set is already available.
排除标准
- •Pregnant, parturient or breast-feeding women
- •Minor (not emancipated)
- •Person of legal age (subject to a legal protection measure)
- •Adult unable to give consent
结局指标
主要结局
MAP1 homocysteinylation level
时间窗: Baseline
次要结局
- Homocysteinylation level of tau protein(baseline)
研究者
RENAUD Mathilde
Principal investigator
Central Hospital, Nancy, France